price month
initi coverag outperform
impress portfolio
regen leader posit drive market share margin
initi coverag target price outperform rate
assembl
regen medicin
differenti product key growth segment within wound care
posit view base clear opportun gain share high-
growth adjust upcom reimburs chang improv
margin driven mix improv oper leverag
amniot tissu share gain differenti execut
orgo affin fresh amniot membran product differenti
appear deliv efficaci top end rang even
challeng chronic wound nushield compet dehydr amniot
tissu market differenti retain layer natur
amniot tissu remov manufactur estim
offer back wide product portfolio distribut network
enabl reach share high-margin market
target biofilm purapli
antimicrobi collagen matrix use similarli tissu graft
ad benefit help control biofilm bacteria purapli one
orgo import growth margin driver expect
continu despit expect transit reimburs
valuat target price deriv ev/sal project
ntm sale mil one year today multipl assum
expans current level discount regen
comp factset consensu risk delay key product
litig
lt plan object potenti
progress
valuat metric
number share
nm composit
close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
compani develop manufactur commerci drug
medicin wound care surgic sport medicin market
one-year valuat scenario base
ev/sal multipl ntm sale mil one-
year forward scenario base high-growth
segment declin core growth segment grow
one-year valuat grey scenario base
ev/sal multipl grey ntm sale mil
one-year forward grey scenario base high-growth
segment declin core growth segment grow
nm composit close
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
tabl content
differenti regen product drive share growth market
sustain double-digit underli growth adjust purapli pass-thru
overview major busi line
compani background histori
financi statement project
charl martineau pm univers toronto given dd growth
wound segment
expect
share loss
mdxg estim
reach
market share
growth continu
expir pass-
statu late
digit growth total
sale expect
favor growth
margin help
off-set impact gm
figur nushield affin drive share gain amniot tissu market
figur estim purapli trend total sale growth adjust
expect purapli price reduct late
amniot tissu growth estimate amniot market growthnushieldand affin drive share gain inmkt share gain total sale growth purapli unit unitsadj sale charl martineau pm univers toronto
surgic
figur broad portfolio skin substitut
broad
portfolio skin
substitut address
wound across
result better
initi coverag organogenesi outperform target price
invest thesi base clear opportun gain share high-valu
adjust upcom reimburs chang improv margin driven mix
improv oper leverag main competitor includ mimedx group mdxg
integra lifesci acel smith nephew snn recent acquir
osiri see figur believ stock attract current level
amniot tissu share gain differenti execut
compani affin fresh amniot membran product differenti base
check clinician appear deliv efficaci top end rang
even challeng chronic wound expect result random
multi-cent studi complet last year publish peer-review journal year
nushield compet dehydr market differenti maintain
layer natur amniot tissu remov manufactur combin
offer back orgo wide breadth product offer
distribut network enabl compani captur share high-margin market
estim gain market share mil
given double-digit growth wound segment recent year
expect share loss market leader mdxg believ
project reason may conserv perspect
expect mdxg share loss total believ
posit captur littl less half
double-digit growth sustain despit expect transit reimburs
driven combin growth wound product growth sport core
wound care product expect portfolio manag upcom
transit purapli pass-through coverag statu back bundl reimburs
pass-through wound care clinic bill medicar directli cost
product manag transit purapli pass-through coverag
bundl coverag expect experi posit compani
proactiv address econom chang custom
particular expect declin purapli volum modest due
primarili proactiv step manag price estim gross margin
roughli flat vs declin bp vs given offset
leverag across busi favor mix product expect
gross margin improv resum bp per year
valuat target price deriv ev/sal project ntm sale
mil one year today multipl assum expans current
level remain discount regen comp base
factset consensu
failur show progress toward long-term orgo interim
long-term financi goal lay rang object target relat sale
growth gross margin ebitda margin compani unabl achiev
target could materi advers impact price perform sharehold
potenti delay failur product approv launch timelin
clinic timelin reimburs compani track launch number
import new product failur bring new product market
quickli improv exist product may result compani fail achiev
long-term financi goal product becom obsolet custom switch
competit product could materi impact compani
revenu profit addit chang insur coverag polici
reimburs regulatori chang relat compani product
procedur could hurt compani busi
slower expect uptak commerci adopt product slower
adopt traction key product especi dermagraft apligraf purapli
could materi advers impact compani revenu market share
assumpt well price perform sharehold return
addit regulatori approv result novemb fda hct/p
guidanc compani may revis label market claim
affin nushield amniot membran may obtain fda approv
bla nucel renu
interrupt product suppli product affin fresh amniot
allograft suspend due product issu one compani supplier
supplier implement certain correct measur
determin current process meet compani product
standard identifi altern supplier howev product affin
expect commenc earliest disrupt suppli
result reduc affin revenu potenti materi impact sale growth
new fda quality-rel issu extend remedi fda warn
letter warn letter could result signific modif compani
oper potenti recal inabl obtain futur pre-market approv
remov current product market result addit remedi cost
potenti delay disrupt product approv avail
share growth market
well-posit gain share regen
known among wound care specialist larg establish provid wound
care product inpati outpati set acquisit nutech
subsequ challeng emerg market leader high-
valu amniot tissu segment wound care market becam well
posit drive share segment amniot tissu segment repres
approxim half skin substitut wound care market approxim
mil sale grow annual mdxg market leader
lose share consist altern tissu matrix product well
amniot tissu product includ orgo nushield affin acquir
nutech
competit combin product hand larg connect field forc
mani wound care specialist familiar dehydr product
mimedx epifix remain wide known orgo nushield product compet
categori howev distinct maintain spongi layer
amnion chorion may help support vascular new tissu product
avail size support larg establish field forc enabl
compani take share segment affin slightli differenti
fresh amniot membran clinician familiar product believ perform
high end rang success support closur difficult chronic wound
expect result random control studi support efficaci
product particularli tougher chronic wound
estim reach market share mil
given doubl digit growth wound segment expect
share loss mdxg believ project reason conserv
perspect expect mdxg share loss total
believ posit captur littl less half estim share
acquisit nutech summar estim growth
share gain
figur nushield affin drive market share gain amniot tissu market
amniot tissu growth estimate amniot market growthnushieldand affin drive share gain inmkt share gain charl martineau pm univers toronto
growth adjust purapli pass-thru
orgo portfolio deliv double-digit long-term growth
driven combin growth wound product growth sport core
wound care product expect portfolio manag upcom
transit purapli pass-thru coverag statu back bundl reimburs
pass-thru wound care clinic bill medicar directli cost product
time upcom transit purapli around one-third
busi grow singl digit estim comparison expect
grow sport grow manag
transit purapli pass-thru coverag bundl coverag
expect experi process posit compani proactiv
address econom chang custom particular expect
declin purapli volum modest due primarili proactiv
step manag price summar growth assumpt purapli
unit total sale growth adjust project purapli price reduct
what special purapli
product seen strong adopt among wound care specialist driven abil
control biofilm chronic wound begin grow re-establish
day wound debrid product bundl price similar tissu
graft effect biofilm differenti product
margin impact notic manag
product like nushield affin purapli compani next profit
product gross margin basi result estim headwind gm
face headwind respect given offset
leverag across busi favor mix product estim gm
roughli flat vs declin bp vs
expect gm improv resum bp per year
figur estim purapli trend total sale growth adjust purapli price reduct
market share gain mdxg market leader amniot tissu segment
lose share consist altern tissu matrix product well
amniot tissu product includ orgo nushield affin
acquir nutech given doubl digit growth wound segment
expect share loss mdxg expect mdxg share loss
total believ posit captur less
half estim market share mil revenu
purapli pass-through statu pass-through statu purapli purapli
extend septemb product transit back
bundl payment structur repres slowdown growth start octob
manag transit purapli pass-thru coverag
bundl coverag expect declin purapli volum
modest due primarili proactiv step manag price
diversifi portfolio estim headwind gm
respect howev given offset leverag across
busi favor mix product estim gm roughli flat
vs declin bp vs expect gm improv
resum bp per year subsequ three year
earn may compani report second quarterli earn
newli public compani may expect updat advanc
wound surgic sport medicin segment well addit color
sale rep add purapli contribut quarter
new product launch on-going new product launch execut recent
launch product also key stock driver upcom key product launch includ
purapli xt enhanc thick version purapli mz micron particul
version purapli awc well puraforc bioengin porcin collagen surgic
matrix use soft tissu reinforc applic ssm compani
expect commerci novachor fresh chorion membran treatment
chronic acut wound transcyt bioengin tissu scaffold promot
burn heal awc addit compani complet random multi-
center studi evalu use nushield affin fresh amniot membran vs
standard care patient neuropath diabet foot ulcer would expect
public result
productbusi linedescriptionlaunch yearregulatori pathwayclin applicationpurapli xtawc ssmversion purapli enhanc thick phmb acut wound except degre burn purapli mzawc ssmmicron particul version purapli treatment chronic acut acut wound except degre burn puraforcessmbioengin porcin collagen surgic tendon bodynovachorawcfresh chorion membran contain viabl cell growth factors/cytokin extracellular matrix protein treatment chronic acut hct/pchronic acut woundstranscyteawcbioengin tissu scaffold promot burn second degre charl martineau pm univers toronto
clinic trial pipelin on-going compani conduct number import
clinic trial support physician payor adopt orgo product
tabl highlight import clinic trial upcom mileston
productindicationdesignanticip completionacut chronic patient singl center control prospect evaluationcomplet accept publicationacut chronic patient singl center control prospect evaluationcomplet public progressacut chronic patient center patient registri evalaut real-world effect ppamenrol complet final data woundscompar effect analysi ppam treatmnet vlu util larg wound databasedata track volum adequ analysispressur patient two center random control clinic trial ppam vs standar second deggre patient multicent random clinic trial evalaut heal cosmesi econom outcom vs standard careon hold pend commercializationapligrafvluscompar effect analysi apligraf treatmnet vlu util larg wound databaseapligraf vs primatrix epublishedapligraf vs epifix patient two center random control clinic trial affin vs standar patient prospect studi evalu potenti chang wound microenvironmentcomplet final data manuscript patient random control clinic trial vs standar careiniti first patient complet patient random control clinic trial vs standar carestart process initi complet spine vertebr patient prospect efficaci studi nucel patient undergo fusion one two three level degenera diseas lumbar spine vertebr patient single-arm prospect multi-cent studi nucel patient receiv interbodi fusion one two three level degenera diseas lumbar patient pilot studi renu hip inject monitor resporis hip function pain patient defect patient evalu renu amniot suspens allograft marrow stimul treatment ostechondr patient compar studi inject human amniot allograft renu vs corticosteriod plantar fasciti prospect random blind patient investig renu knee inject monitor respons knee function pain patient clinic trial pipelin sm clinic trial charl martineau pm univers toronto
loss purapli pass-through statu pass-through statu purapli
purapli extend septemb product
transit back bundl payment structur repres slowdown growth
start octob product transit bundl payment
expect asp drop repres slowdown purapli sale
start context purapli repres sale
overview major busi line
organ two main segment advanc wound surgic
sport medicin figur provid overview major busi line
size geograph mix growth profil well primari competitor key
figur sale major busi line geographi
sale geographi
figur overview major busi line
advanc wound sport cagrcomp productsadvanc wound careproduct treatment chronic acut wound primarli outpati forwardmdxg acel osiri solsi acel amniox snnapligraf treatment diabet foot ulcer dfu venou leg ulcer vlu dermagraft dfu purapli affin nushield varieti wound size typessurg sport medicineproduct musculoskelet injuri degen condit like tendon forwardmdxg acel osiri wmgim renu in-offic joint tendon applic nucel boni fusion spine extrem nushield affin surgic applic soft tissu repair purapli treatment open charl martineau pm univers toronto
target price reflect market share gain improv margin
target price deriv ev/sal project ntm sale mil
one year today multipl assum expans current level
remain discount regen comp outperform rate
invest thesi driven clear opportun gain share high-valu
high-growth amniot tissu segment sustain double-digit growth adjust
upcom reimburs chang improv margin driven mix improv
share price april cs target price
one-year valuat scenario base
ev/sal multipl ntm sale mil one-year forward
scenario base high-growth segment declin core
growth segment grow
grey one-year valuat grey scenario base
ev/sal multipl grey ntm sale mil one-year
forward grey scenario base high-growth segment declin
core growth segment grow
risk target price rate follow
failur show progress toward long-term orgo interim
long-term financi goal lay rang object target relat sale
growth gross margin ebitda margin compani unabl achiev
target could materi advers impact price perform sharehold
potenti delay failur product approv launch timelin
clinic timelin reimburs compani track launch number
import new product failur bring new product market
quickli improv exist product may result compani fail achiev
long-term financi goal product becom obsolet custom switch
competit product could materi impact compani
revenu profit unfavor result unforeseen circumst
relat compani clinic program could result delay failur
regulatori approv new product plan modif
expans exist product addit chang insur coverag polici
reimburs regulatori chang relat compani product
procedur could hurt compani busi specif pass-through statu
purapli purapli extend septemb
product schedul transit back bundl payment structur
repres slowdown growth start octob potenti
advers event challeng materi affect oper cost potenti
sale growth compani
slower expect uptak commerci adopt product slower
adopt traction key product especi dermagraft apligraf purapli
could materi advers impact compani revenu market share
assumpt well price perform sharehold return wound care
profession may slow adopt compani product due lack familiar
orgo product prefer competitor product cheaper altern
competitor apligraf dermagraft premium price product
focus sever dfu vlu face consider competit
competitor lower-pr non-pma approv product
addit regulatori approv renu nucel affin nushield current
regul hct/p novemb fda issu final guidanc
document hct/p guidanc stipul hct/p minim
manipul intend homolog use result guidanc
compani may revis label market claim affin nushield
amniot membran product ensur meet homolog use
requir hct/p perform basic function donor recipi
continu qualifi section hct/p addit compani
obtain fda approv bla nucel renu product may
deem minim manipul degre origin
characterist hct/p alter may regul
hct/p event nucel renu deem hct/p
complianc applic regulatori requir involv signific time
substanti cost compani may requir suspend sale nucel
renu fda approv obtain howev hct/p guidanc provid
month grace period allow suffici time distributor hct/p make
regulatori submiss obtain pre-market approv necessari complianc
compani unabl obtain bla approv nucel renu within
month grace period sale product would suspend
interrupt product suppli product affin fresh amniot
allograft suspend due product issu one compani supplier
supplier implement certain correct measur
determin current process meet compani product
standard identifi altern supplier howev product affin
expect commenc earliest disrupt suppli
result reduc affin revenu potenti materi impact sale growth
new fda quality-rel issu extend remedi fda warn
letter orgo product regul fda non-compliance
regulatori requir could result potenti warn letter warn letter
may lead signific modif compani oper potenti recal
inabl obtain futur pre-market approv remov current product
market remedi warn letter consist comprehens plan
correct action could drawn materi advers effect
compani term addit remedi cost potenti delay disrupt
product approv avail compani current
outstand warn letter fda
organogenesi report revenu two major categori advanc wound
revenu surgic sport medicin revenu discuss
detail almost compani revenu gener
physician offic
figur revenu segment
figur revenu geographi
mil sale compound-annual-growth-rate
advanc wound awc compani focus develop
commerci advanc wound care product treatment chronic
acut wound primarili outpati set offer comprehens portfolio
product collagen biomateri technolog product amniot placent product
apligraf bioengin bi-lay skin substitut treatment vlu
venou leg ulcer dfu diabet foot ulcer
dermagraft dermal substitut grown human dermal fibroblast
treatment dfu
purapli purifi nativ collagen matrix promot heal address
biofilm across broad varieti wound type
affin fresh amniot allograft applic care chronic
acut wound surgic implant spine orthoped sport medicin
applic
nushield dehydr placent tissu graft address varieti wound
size type
compani market lead posit across portfolio strong brand
recognit among clinician awc product sold compani special
direct wound care sale forc context compani direct sale
repres independ agenc decemb
compani product compet skin substitut well advanc wound
care product npwt growth factor addit purapli also compet
antimicrobi dress manufactur non-amniot product in-hous
use third-parti manufactur amniot product
apligraf launch bioengin bi-lay skin substitut
product receiv pma approv treatment vlu
dfu apligraf includ outer layer protect skin cell human epiderm
keratinocyt inner layer cell human dermal fibroblast contain within
collagen matrix apligraf one compani flagship product play
activ role heal provid wound live human skin cell growth
factor protein
figur apligraf provid live cell growth factor
productdescriptionlaunch yearregulatori pathwayclin applicationproduct portfolio apligrafbioengin live cell therapi contain two live cell type keratinocyt fibroblast produc broad spectrum cytokin growth dfusdermagraftbioengin product live human fibroblast seed bioabsorb scaffold produc human collagen ecm protein cytokin growth placent tissu graft preserv retain layer nativ tissu includ amnion chorion membran epitheli layer spongy/ intermedi layer hct/pchronic acut woundsaffinityfresh amniot membran contain mani type viabl cell growth factors/cytokin ecm hct/pchronic acut woundspurapli ampurifi nativ collagen matrix broadspectrum polyhexamethylen biguanid phmb antimicrobi chronic acut wound except degre charl martineau pm univers toronto
pivot studi initi conduct apligraf demonstr safeti
efficaci product treatment full- partial-thick vlu dlu
dfu indic multi-cent prospect rct apligraf treatment
dfu versu standard care conduct patient type
diabet plantar dfu full partial thick enrol studi
patient ulcer off-load use either crutch wheelchair first
six week follow custom pressure-reliev footwear least four week
post closur apligraf significantli effect convent therapi
incid complet wound closur time week treatment
patient dfu treat apligraf plu convent therapi
close compar subject ulcer treat convent
therapi alon median time wound closur day dfu
treat apligraf plu convent therapi versu day ulcer treat
convent therapi alon addit studi ulcer treat
apligraf remain close six month versu control group
vlu pivot trial efficaci apligraf evalu prospect
parallel-group random control multi-cent studi involv patient
vlu apligraf plu compress therapi effect achiev complet
wound closur week vs patient long-stand
vlu greater one year durat apligraf plu compress
therapi twice effect achiev complet wound closur
figur dfu treat apligraf
close week vs convent
figur vlu treat apligraf
demonstr wound closur week vs
convent therapi alon
compani also conduct three compar effect studi
apligraf util data collect net health woundexpert electron medic
record databas outcom treatment apligraf compar skin
substitut includ epifix mimedx theraskin solsi medic llc oasi
smith nephew analyz three studi show apligraf improv
overal heal rate well time heal
dermagraft launch smith nephew acquir
dermal substitut grown human dermal fibroblast cell within
dermi layer skin respons gener connect tissu
allow skin recov injuri dermagraft pma approv
treatment dfu product appli weekli eight time
period need remov wound temporari
mesh fabric dissolv becom part bodi heal process
figur dermagraft contain temporari mesh fabric dissolv
becom part bodi heal process
dermagraft approv class medic devic treatment dfu
base result larg pivot clinic trial patient enrol
prospect rct evalu safeti efficaci dermagraft conjunct
convent therapi compar control arm convent therapi alon
patient random one two treatment group dermagraft plu
convent therapi convent therapi alon patient dermagraft group
receiv weekli applic dermagraft convent therapi eight
week primari endpoint trial superior complet dfu closur
week weekli applic dermagraft convent therapi
week increas proport dfu achiev closur week
compar use convent therapi alon addit percentag
patient develop infect dfu site significantli lower
dermagraft treatment group compar control group
figur dfu close week vs convent therapi
nushield launch nutech medic acquir
dehydr placent tissu graft topic surgic appli target
tissu support wound heal nushield process compani
proprietari bioloc process preserv nativ structur amnion
chorion membran includ intermedi spongi layer reservoir
growth factor protein nushield avail varieti size
store room temperatur five year shelf life product regul
human cell tissu cellular tissue-bas hct/p section
figur nushield topic surgic appli support heal
acut chronic wound
affin launch nutech medic acquir
fresh amniot allograft applic care chronic acut
wound surgic implant spine orthoped sport medicin applic
affin contain viabl amniot cell undergo compani proprietari
allofresh process hypotherm store product fresh state
dri frozen help retain product nativ benefit structur affin
also regul hct/p
figur affin treat chronic acut wound tendon ligament
purapli antimicrobi skin substitut develop
address challeng pose bioburden number microorgan
object contamin affect heal rate wound excess
inflamm wound purapli purifi nativ porcin type collagen
matrix embed polyhexamethylen biguanid phmb local
broad spectrum antimicrobi combin phmb nativ collagen matrix
help manag bioburden support wound heal purapli skin substitut
antimicrobi properti appropri treatment wound biofilm thin
film bacteria adher surfac compet antimicrobi dress
product launch approv manag
wide varieti wound includ partial full-thick wound pressur ulcer
surgic wound trauma wound drain wound first- second-degre
burn compani also clearanc purapli without phmb
purapli patient requir antimicrobi agent either kill slow
growth microb
figur purapli effect combin phmb nativ collagen
matrix support heal across wide varieti wound type
compani also robust pipelin product awc address patient need
chronic acut wound burn surgic treatment open wound
purapli xt enhanc thick version purapli phmb content
allow sustain presenc antimicrobi barrier wound
purapli xt intend indic treatment chronic
acut wound degre burn surgic treatment open
wound xt expect launch
purapli mz micron particul version purapli allow applic
powder gel form deep tunnel wound mz intend
indic treatment chronic acut wound degre
burn surgic treatment open wound mz expect launch
novachor fresh chorion membran contain viabl cell growth
factors/cytokin extracellular matrix ecm protein treatment
chronic acut wound novachor expect launch
regul hct/p
transcyt bioengin tissu scaffold promot burn heal
receiv pma approv treatment second- third-degre burn
provid bioactiv dermal
compon outer protect barrier increas re-epitheli pain
relief patient suffer burn transcyt acquir shire
previous market smith nephew current market
expect commerci transcyt target burn
annual requir hospit compani expect mil
growth driver awc includ penetr deeper advanc wound
market leverag compani product portfolio well key custom
relationship orgo broad product portfolio allow compani address wide
varieti wound type size also reimburs level compani
invest physician payor awar program educ physician payor
benefit regen medicin compar compar tradit
therapi addit compani also plan introduc addit size
purapli smaller size apligraf pma supplement allow
physician flexibl manag reimburs set
mil sale compound-annual-growth-rate
surgic sport medicin ssm compani develop product support
heal musculoskelet injuri includ degen condit
osteoarthr tendon ssm compani focu regen
orthobiolog base amniot product use help injuri heal
quickli also treat peopl long-term disabl musculoskelet disord
injuri compani enter surgic sport medicin market
acquisit nutech medic ssm product sold independ
distributor well compani direct sale forc provid overview
compani key ssm product
productdescriptionlaunch yearregulatori pathwayclin applicationpipelin purapli xtversion purapli enhanc thick phmb acut wound except degre burn purapli mzmicron particul version purapli treatment chronic acut acut wound except degre burn novachorfresh chorion membran contain viabl cell growth factors/cytokin extracellular matrix protein treatment chronic acut hct/pchronic acut woundstranscytebioengin tissu scaffold promot burn second degre charl martineau pm univers toronto
figur renu use support heal soft tissu
renu in-offic joint tendon applic inject renu cryopreserv
suspens deriv human amniot tissu amniot fluid set
support heal soft tissu particularli degen condit oa
joint tendon injuri renu current regul hct/p
product
manag believ could open signific opportun includ potenti
physician util j-code administr product manag
estim address bil market opportun ha inject
estim long-term sale potenti renu excess mil
work
figur nucel use primarili spinal orthoped surgic applic
nucel boni fusion spine extrem nucel surgic implant
allograft deriv human amniot tissu amniot fluid use primarili
spinal orthoped surgic applic nucel current regul
hct/p clinic effort underway secur bla-approv product
ssm product compani also manufactur bone allograft product
osteoin fibero ocmp deriv donat human cadaver
bone osteoin deminer bone matrix putti mold press
bone void filler fibero blend deminer cortic fiber
miner cortic powder deminer cortic powder ocmp
freeze-dri allograft cancel spongi mesh-lik deminer cortic
mixtur product use bone void filler orthoped neurosurg
applic requir boni fusion spinal fusion foot ankl fusion
sold supplementari product togeth nucel
compani also expect market sever key wound heal product
describ detail ssm set includ nushield dehydr
placent tissu graft affin fresh amniot membran purapli manag
expect product use target surgic applic soft tissu
repair adhes barrier on-lay wrap soft tissu repair surgic
compani expect leverag commerci oper infrastructur
well direct sale forc supplement independ distributor network
cross-sel within establish custom base penetr ssm
market addit compani believ potenti regen medicin
ssm treat chronic inflammatori degen condit long-term
opportun context osteoarthr oa common chronic condit
joint affect mil peopl compani see bil
market opportun ha inject
compani pipelin ssm includ includ regen orthobiolog
address wide varieti musculoskelet injuri product includ purapli
xt mz discuss sold surgic call point well
puraforc bioengin porcin collagen surgic matrix use soft
tissu reinforc applic product intend indic
reinforc tendon bodi expect
commerci launch
productdescriptionlaunch yearregulatori pathwayclin applicationproduct portfolio nucelcellular suspens stem cell-contain allograft deriv human amnion tissu amniot hct/porthoped surgic procedur includ boni fusionnushielddehydr placent tissu graft preserv retain layer nativ tissu includ amnion chorion membran epitheli layer spongy/ intermedi layer hct/ptendon ligament soft tissu injuriesaffinityfresh amniot membran contain mani type viabl cell growth factors/cytokin ecm hct/ptendon ligament soft tissu injuriespurapli ampurifi nativ collagen matrix broadspectrum polyhexamethylen biguanid phmb antimicrobi surgic treatment open woundsrenucryopreserv suspens amniot fluid cell morsel amnion tissu hct/pchronic inflammatori degen condit soft tissu injuri tendinosi fasciitisproductdescriptionlaunch yearregulatori pathwayclin applicationpipelin puraforcebioengin porcin collagen surgic tendon bodygintuitsurg appli bioengin bi-lay live cellular tissu -- blasurg treatment oral soft charl martineau pm univers toronto
surgically-appli bioengin bi-lay live cellular tissu
support heal oral soft tissu bla approv product
base cultur allograft cell indic treatment mucogingiv
condit adult product current market compani plan
commerci futur via partnership oral surgeri market
context obtain fda approv bla oral tissue-engin
product market trade name
intend use pediatr popul fda impos requir
conduct pediatr studi follow approv compani origin
plan complet studi manag made decis suspend
commerci notifi fda decis june
fda notifi compani compli pediatr
research equiti act prea oblig requir bla product carri
clinic
requir waiv compani subsequ submit formal request
extens pediatr studi requir request
deni octob compani believ use
product pediatr popul howev decid go
market product could view misbrand subject
enforc action market resum without complet requir
pediatr popul unless
trial
product
market growth driver includ age popul greater incid comorbid
diabet obes cardiovascular peripher vascular diseas
smoke along increas accept advanc technolog treat
complex wound musculoskelet injuri
bil compound-annual-growth-rate
wound classifi either chronic acut estim
mil patient suffer chronic acut wound global year
estim chronic wound account three-quart wound distribut
type acut wound make remain quarter total wound
advanc wound market estim bil grow
wound care market includ tradit dress bandag gauz
ointment well advanc wound care product mechan devic
advanc dress biolog advanc wound care product target chronic
acut wound adequ address tradit therapi
figur adv wound market product segment bil compound-annual-growth-rate
biolog repres bil advanc wound care market
fastest grow segment advanc wound care market skin substitut
bil biolog market grow mid-teen driven physician educ
clinic evid demonstr benefit skin substitut tradit
chronic wound wound properli close four week
tradit treatment dress account major spend
given complex length treatment chronic wound includ vlu
wound occur leg vein blood circul properli
heart dfu open sore wound occur patient diabet commonli
locat bottom foot pressur ulcer local injuri skin
tissu result pressur surgic wound
acut wound caus surgic incis becom chronic wound
heal properli
acut wound injuri caus rapid break skin sometim
underli tissu sever overwhelm bodi normal heal
capac acut wound
traumat wound abras
lacer penetr injuri burn surgic wound surgic incis
approxim open traumat wound excess burn
requir medic treatment burn requir hospit
figur adv wound market major categori bil compound-annual-growth-rate
compani product regul fda approv
approv class ii medic devic pre-market
submiss made fda demonstr devic market
least safe effect legal market devic compani
purapli purapli product receiv approv
pma pre-market approv fda process scientif regulatori
review evalu safeti effect class medic devic
typic involv one prospect random multicent clinic
trial pma rigor type devic market applic
requir fda apligraf dermagraft pma approv
bla approv pertain biolog product either regul
section hct/p subject regulatori requir biolog
section phsa
tissu cellular
tissue-bas product regul hct/p may
commerci distribut without prior fda clearanc approv
order regul hct/p hct/p must minim
manipul intend homolog use manufactur without
combin anoth articl hct/p must also either
system effect depend upon metabol
activ live cell primari function hct/p
requir fda approv subject specif fda regul
includ cgtp current tissu practic donor elig
determin requir advers event report advertis
label requir compani affin nushield
meet definit hct/p
bla hct/p meet criteria regul
biolog product must receiv bla biolog licens
applic approv section public health servic
act ph ph requir firm manufactur biolog sale
interst commerc hold licens product bla
manufactur
process chemistri pharmacolog clinic pharmacolog
medic effect biolog product orgo nucel renu
bla
inform
bil compound-annual-growth-rate
ssm market target bil grow around
annual market growth driven increas surgic volum
result higher incid comorbid chronic inflammatori
degen condit growth also driven increas spinal fusion bone
reconstruct surgeri musculoskelet injuri degen condit
spinal fusion surgic procedur use correct problem small
bone spine fuse togeth two vertebra heal
singl solid bone non-union due inadequ bone heal one
lead caus failur fusion procedur fusion especi
challeng patient comorbid diabet obes
smoke autograft bone marrow histor use biolog
support bone heal lead vari outcom due underli
health condit patient bone fusion perform
year
tendon ligament injuri common orthoped condit
activ age popul rotat cuff repair
achil tendon repair perform annual re-ruptur
reoper continu remain issu surgeri
comorbid age also correl higher risk fail heal
re-ruptur
chronic inflammatori degen orthoped condit
common age popul osteoarthr oa common
chronic condit joint affect mil peopl
chronic inflammatori condit achil rotat cuff tendinosi
plantar
increasingli common oa
degen condit typic treat inject steroid
hyaluron acid ha inject offer pain relief limit time
fasciiti also
bone morphogenet protein bmp famili protein stimul
bone growth natur human bodi creat fusion without
need use patient bone bmp use orthoped
applic spinal fusion non-union oral surgeri
viscosupplement procedur thick fluid compris
hyaluron hydraul acid inject knee joint pain relief
associ osteoarthr hyaluron improv lubric
properti synovi fluid reduc pain osteoarthr
knee provid temporari relief patient yet readi indic
synthet bone graft substitut artifici produc either bulk
extend suppli avail autograft bone bone harvest
patient bodi synthet bone graft work process call
osteoconduct mean bone grow surfac
donor harvest bone process remov blood cell
miner
allograft cadaver bone usual obtain bone bank rather
patient
compani product cover medicar medicaid well privat
payor custom includ hospit wound care center govern facil
physician offic current outpati set orgo product
skin substitut bundl payment applic procedur
except product approv pass-through statu like purapli
purapli medicar make separ payment orgo product use
physician offic payment rate averag sale price plu asp
skin substitut product administ hospit outpati depart
set bundl except product approv
pass-through statu drug devic pass-through statu facil use
design drug devic receiv extra payment higher reimburs
product limit time usual year purapli purapli product
approv pass-through statu januari decemb
highlight pass-through statu timelin purapli purapli
januari compani purapli purapli
product approv pass-through statu januari
januari purapli purapli includ
march march appropri act restor
pass-through statu purapli purapli
octob pass-through statu purapli purapli
restor effect octob statu continu
septemb medicar make pass-through payment
purapli purapli use outpati hospit set
octob march pass-through payment equal
pass-through amount appli decemb asp
octob purapli purapli transit back bundl
payment structur pass-through statu appli medicar
medicaid privat payor appli compani
center medicar medicaid servic administ medicar program
use medicar administr contractor process claim develop
coverag polici make payment within design geograph jurisdict orgo
product fall jurisdict part a/b medicar coverag
orgo product establish specif jurisdict context
privat health care insur award geograph jurisdict
process medicar part part a/b medic claim medicar fee-for-servic
ff beneficiari current cover compani product
outpati hospit physician offic set privat payer current
cover apligraf dermagraft cover product purapli purapli
nushield affin
wound reimburs orgo advanc wound product
classifi skin substitut medicar reimburs purpos bundl
payment hospit outpati depart set skin
substitut mean singl payment made includ
applic product product also classifi skin
substitut low cost high cost group base weight per squar
centimet averag bundl payment rate updat annual also
geograph adjust threshold determin product
assign high cost bundl also adjust year current
orgo wound care product assign high cost bundl
physician offic set payment skin substitut bundl
paid separ applic procedur medicar payment rate
skin substitut calcul base manufactur asp per
squar centimet basi physician offic set medicar payment
rate skin substitut updat quarterli base manufactur
report asp geograph adjust actual payment rate
skin substitut asp asp adjust statutorili mandat
product administ inpati basi hospit reimburs
medicar part bundl payment base medicar sever
consolid prospect payment servic provid hospit
patient hospit base averag cost care calcul
medicar claim data product administ surgic procedur
typic code paid separ therefor reimburs
singl bundl drg payment hospit must cover
expens associ procedur except physician fee
gari gillheeney sr presid ceo mr gillheeney appoint presid
ceo januari previous serv compani
cfo prior join organogenesi mr gillheeney held
variou execut posit innov clinic solut chief
oper offic chief offic well treasur secretari
join innov clinic solut held posit senior vice presid chief
financi offic treasur assist secretari provid energi corpor
timothi cunningham cfo mr cunningham appoint cfo januari
prior join organogenesi serv chief offic vestigo
ventur previous serv senior vice presid chief offic
dialogtech world-wide vice presid financ oper gfi
softwar sa execut vice presid chief offic
metatomix senior vice presid chief offic
mediabridg
patrick bilbo mr bilbo appoint januari previous
held variou execut posit includ senior vice presid
regulatori govern affair administr prior join organogenesi
serv director regulatori clinic affair cytyc corpor
brian grow mr grow appoint sinc previous held
variou execut posit includ director sale commerci oper
associ director market project manag apligraf
region sale manag tissu regener specialist
prior join organogenesi serv sale repres bristol-
myer squibb tissu engin specialist innovex/novarti
antonio montecalvo vice-president health polici contract mr montecalvo
appoint vice-president role sinc previous held variou execut posit
includ director custom support servic prior organogenesi
serv director account innov clinic solut senior
contract specialist unitedhealth group senior account
piccerelli gilstein compani llp
howard walthal evp strategi market develop mr walthal appoint
evp role sinc prior join organogenesi serv presid ceo
nutech medic previous held variou leadership role
nutech acquisit organogenesi prior join nutech mr walthal
partner burr forman llp serv adjunct professor
univers alabama school law
compani background histori
compani found spin-off technolog develop mit
decemb avista healthcar public acquisit corp complet busi
combin organogenesi inc direct wholli own subsidiari
organogenesi inc avista merger account revers
merger accord ahpac treat acquir compani
account purpos decemb compani approxim
march compani acquir nutech medic inc mil cash
mil paid close remaind due paid
anniversari close part deal compani agre make four quarterli
payment mil first year follow close less mil adjust
work capit payment mi anniversari close
decemb mil remain payabl nutech acquisit allow
compani enter surgic sport medicin market compani acquir
nucel launch nushield launch affin launch
renu launch product nutech
prior compani acquir dermagraft transcyt shire plc januari
mil cash februari compani acquir nanomatrix
inc undisclos amount compani special electrospin techniqu
use assembl nano-scal fiber three-dimension scaffold use
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag inform see novemb
financi statement project
mm except per share incom exp inc inc exp dilut rate incom gm mid gm sg high sg ebitda ebitda breakevenltp ebitda mgn charl martineau pm univers toronto
wound sport mid teensltp charl martineau pm univers toronto figur balanc sheet
mm except per share short-term exp current intang term non-curr current current long-term non-curr common comp inc stockhold liabil sheet payabl debt debt charl martineau pm univers toronto figur statement flow
mm except per share flowsnet incom base non-cash work asset oper flowscapit use stock issuanc common fx chang convers convers charl martineau pm univers toronto
compani mention price
